Goldberg Comments On Trump Lowering The Costs Of Drugs
In a heated and, at times, bizarre exchange on ABC’s The View, the cohosts took aim at former President Donald Trump’s plan to reduce prescription drug costs—an initiative that, ironically, has found allies on both sides of the aisle. But instead of tackling the policy on its merits, the segment quickly unraveled into tangents, contradictions, and personal jabs that revealed more about partisan frustration than the actual substance of the proposal.
Whoopi Goldberg opened the discussion with skepticism, arguing that Trump’s plan lacked clarity. She questioned which drugs and insurance plans would be affected, noting that unless the root problems within the insurance industry were addressed, lowering drug prices would be like applying a band-aid to a bullet wound.
While her critique raised valid concerns about systemic complexity, the tone suggested a deeper discomfort: namely, that it was Trump—not a Democrat—spearheading an initiative long considered a progressive goal.
The View decries Trump’s efforts to lower prescription drug costs because he didn’t say which drugs and because he’s fat:
Whoopi Goldberg: He didn’t specify which drugs he’s going to target or which insurance programs would be impacted because you see, if you’re going to lower… pic.twitter.com/E9cIqna1MK— Nicholas Fondacaro (@NickFondacaro) May 13, 2025
And that’s where the irony thickens. Joy Behar quickly followed by shifting from policy critique to character assault, taking potshots at Trump’s weight and appearance. Rather than focusing on pharmaceutical policy or patient impact, Behar criticized Trump’s self-image and lack of decorum—an off-topic detour that arguably weakened any substantive argument being made.
Meanwhile, Sara Haines attempted to steer the conversation back toward a global perspective, noting that pharmaceutical lobbying isn’t unique to the U.S. But Behar wasn’t having it. She returned to Trump-bashing, this time with a mix of sarcasm and personal insult, effectively derailing the policy debate altogether.
Oddly enough, it was Alyssa Farah Griffin who injected some balance into the discussion, pointing out that elements of Trump’s plan mirrored legislation championed by progressive heavyweights like Bernie Sanders and Ro Khanna.
Griffin’s concern wasn’t about lowering drug prices, but how that would be enforced. To her, the danger lay in potential government overreach—what she called “Soviet-style price controls”—a classic conservative critique.
Then, in an unexpected twist, Goldberg declared that raising taxes to fund affordable medicine “wasn’t socialism,” but rather a necessity for national well-being. It was a revealing moment: a host defending the very mechanics of government-funded healthcare—while disapproving of them when they appear under a Republican banner.